While TSHR and IGF-1R modulation offer effective strategies for TAO, TRβ-selective agonists, DIO-targeting and TH metabolite-based therapies provide new opportunities for managing other ocular diseases. This evidence concerns the gene TSHR and thromboangiitis obliterans.